Rezolute Inc

NASDAQ:RZLTUnited States

Rezolute, Inc. (Rezolute) is a clinical-stage biopharmaceutical company, which is engaged in developing therapies for metabolic diseases related to chronic glucose imbalance. The Company’s lead clinical asset, RZ358, is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. The antibody modifies insulin’s binding and signaling to maintain glucose levels in a normal range, which counteracts the effects of elevated insulin in the body. It is a potential treatment for congenital hyperinsulinism (HI), which is an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase II. The Company is also developing RZ402, an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME) in Phase I.

Contact Information

Headquarters

201 Redwood Shores Pkwy Ste 315REDWOOD CITY, CA, United States 94065-1134

Phone

650-847-1919

Fax

302-636-5454

Executives

Chairman of the Board

Young-Jin Kim

Chief Executive Officer, Principal Financial Officer, Director

Nevan Elam

Co-Founder, Scientist Emeritus

Sankaram Mantripragada

Chief Medical Officer

Brian Roberts

Independent Director

Philippe Fauchet